Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.
Nitichen KittiratchakoolDisorn KulpokinChonticha ChanjamSoamarat VilaiyukSirirat CharuvanijGun PhongsamartParichat KhaosutManasita TanyaRatanavadee NanagaraSira NantapaisarnPattara LeelahavarongPublished in: BMJ open (2020)
The use of standard treatment plus tocilizumab was not cost-effective in the Thai context, which has limited data. However, there is currently no second-line treatment for refractory sJIA in the Thai National List of Essential Medicines; thus, patients must receive higher doses of standard treatment which can cause many side effects. In contrast, tocilizumab showed obvious efficacy in clinical trials in improving treatment response and QoL. Therefore, the price of tocilizumab should be negotiated to reduce the financial impact on the healthcare system.
Keyphrases
- juvenile idiopathic arthritis
- rheumatoid arthritis
- clinical trial
- end stage renal disease
- healthcare
- rheumatoid arthritis patients
- chronic kidney disease
- combination therapy
- disease activity
- ejection fraction
- machine learning
- quality improvement
- systemic lupus erythematosus
- deep learning
- patient reported outcomes
- peritoneal dialysis
- patient reported
- phase iii